| ORIGINAL ARTICLE |
|
| Year : 2020 | Volume
: 6
| Issue : 3 | Page : 253-258 |
|
|
Cost Needed to Treat and Number Needed to Treat Analysis of Drugs for the Treatment of Heart Failure in India
Varghese George1, Krishnamohan Mullavelil1, Ancy Thannikkal Joseph1, Rajeev Aravindakshan2, Denny John3, Cheriyan Koshy1, Krishnan Nair Venugopal1
1 Department of Cardiology, Pushpagiri Medical College Hospital, Thiruvalla, Kerala, India
2 Department of Preventive and Social Medicine, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India
3 Evidence Synthesis Specialist, Campbell Collaboration, New Delhi, India
Correspondence Address:
Dr. Varghese George
Department of Cardiology, Pushpagiri Institute of Medical Sciences and Research Centre, Thiruvalla, Kerala
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jpcs.jpcs_65_20
|
|
|
Introduction: Our aim was to review the cost-effectiveness of guideline-directed medical therapy of heart failure in India and identify drugs that can be made available free of cost or at subsidized rates to the patient population. Methods: Data extracted from ten landmark trials in heart failure was used to compute the number needed to treat (NNT) and cost needed to treat (CNT) of drugs used in heart failure, to prevent cardiovascular mortality and heart failure re-hospitalization using the HDS Plotter-Incremental Cost Effectiveness Calculator. Since various brands (i.e., trade names) with a wide cost range are available in the Indian market, the average retail price in Indian Rupees for the year 2019 was used for the analysis. NNT and CNT of each drug were computed, and the cost-effectiveness was analyzed. The CNT of these drugs was compared with India's per capita Gross Domestic Product (GDP). The WHO recommendation of three times per capita GDP was used as the cost-effectiveness threshold. Results: Medications that were labeled as Class I for the treatment of heart failure were included in our analysis. Ivabradine, valsartan, and angiotensin receptor neprilysin inhibitor (ARNi) did not meet the cost-effectiveness criteria for preventing cardiovascular mortality. For the prevention of heart failure re-hospitalization, all drugs except ARNi met the cost-effectiveness threshold. Conclusion: Any future research would need to consider the compliance factor along with Willingness to Pay to understand the real acceptance of these drugs on the ground in India.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
